Natural history of t(11;14) multiple myeloma

A. Lakshman, M. Alhaj Moustafa, S Vincent Rajkumar, Angela Dispenzieri, Morie Gertz, F. K. Buadi, Martha Lacy, David M Dingli, A. L. Fonder, S. R. Hayman, M. A. Hobbs, Wilson Gonsalves, Y. L. Hwa, Prashant Kapoor, N. Leung, R. S. Go, Yi Lin, Taxiarchis Kourelis, J. A. Lust, Stephen J Russell & 3 others S. R. Zeldenrust, R. A. Kyle, Shaji K Kumar

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 patients with no chromosomal translocation. The median progression-free survival for the three groups were 23.0 (95% confidence interval (CI), 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months, respectively (P<0.01). The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months, respectively (P<0.01). Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months, respectively (P<0.01). The above relationship held true in patients with age <65 years, international staging system (ISS) I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio (HR): 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM are inferior to other standard risk patients.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalLeukemia
Volume32
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Natural History
Multiple Myeloma
Confidence Intervals
Survival
Genetic Translocation
Interphase
Plasma Cells
Fluorescence In Situ Hybridization
Disease-Free Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Natural history of t(11;14) multiple myeloma. / Lakshman, A.; Alhaj Moustafa, M.; Rajkumar, S Vincent; Dispenzieri, Angela; Gertz, Morie; Buadi, F. K.; Lacy, Martha; Dingli, David M; Fonder, A. L.; Hayman, S. R.; Hobbs, M. A.; Gonsalves, Wilson; Hwa, Y. L.; Kapoor, Prashant; Leung, N.; Go, R. S.; Lin, Yi; Kourelis, Taxiarchis; Lust, J. A.; Russell, Stephen J; Zeldenrust, S. R.; Kyle, R. A.; Kumar, Shaji K.

In: Leukemia, Vol. 32, No. 1, 01.01.2018, p. 131-138.

Research output: Contribution to journalArticle

Lakshman, A, Alhaj Moustafa, M, Rajkumar, SV, Dispenzieri, A, Gertz, M, Buadi, FK, Lacy, M, Dingli, DM, Fonder, AL, Hayman, SR, Hobbs, MA, Gonsalves, W, Hwa, YL, Kapoor, P, Leung, N, Go, RS, Lin, Y, Kourelis, T, Lust, JA, Russell, SJ, Zeldenrust, SR, Kyle, RA & Kumar, SK 2018, 'Natural history of t(11;14) multiple myeloma', Leukemia, vol. 32, no. 1, pp. 131-138. https://doi.org/10.1038/leu.2017.204
Lakshman, A. ; Alhaj Moustafa, M. ; Rajkumar, S Vincent ; Dispenzieri, Angela ; Gertz, Morie ; Buadi, F. K. ; Lacy, Martha ; Dingli, David M ; Fonder, A. L. ; Hayman, S. R. ; Hobbs, M. A. ; Gonsalves, Wilson ; Hwa, Y. L. ; Kapoor, Prashant ; Leung, N. ; Go, R. S. ; Lin, Yi ; Kourelis, Taxiarchis ; Lust, J. A. ; Russell, Stephen J ; Zeldenrust, S. R. ; Kyle, R. A. ; Kumar, Shaji K. / Natural history of t(11;14) multiple myeloma. In: Leukemia. 2018 ; Vol. 32, No. 1. pp. 131-138.
@article{4138c60b1d1a42a6b9550a46dd676414,
title = "Natural history of t(11;14) multiple myeloma",
abstract = "Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 patients with no chromosomal translocation. The median progression-free survival for the three groups were 23.0 (95{\%} confidence interval (CI), 20.8-27.6), 19.0 (95{\%} CI, 15.8-22.7) and 28.3 (95{\%} CI, 25.7-30.6) months, respectively (P<0.01). The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95{\%} CI, 64.8-89.3), 49.8 (95{\%} CI, 40.0-60.6) and 103.6 (95{\%} CI, 85.2-112.3) months, respectively (P<0.01). Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95{\%} CI, 67.0-90.7), 58.2 (95{\%} CI, 47.0-76.4) and 108.3 (95{\%} CI, 92.4-140.1) months, respectively (P<0.01). The above relationship held true in patients with age <65 years, international staging system (ISS) I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio (HR): 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM are inferior to other standard risk patients.",
author = "A. Lakshman and {Alhaj Moustafa}, M. and Rajkumar, {S Vincent} and Angela Dispenzieri and Morie Gertz and Buadi, {F. K.} and Martha Lacy and Dingli, {David M} and Fonder, {A. L.} and Hayman, {S. R.} and Hobbs, {M. A.} and Wilson Gonsalves and Hwa, {Y. L.} and Prashant Kapoor and N. Leung and Go, {R. S.} and Yi Lin and Taxiarchis Kourelis and Lust, {J. A.} and Russell, {Stephen J} and Zeldenrust, {S. R.} and Kyle, {R. A.} and Kumar, {Shaji K}",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/leu.2017.204",
language = "English (US)",
volume = "32",
pages = "131--138",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Natural history of t(11;14) multiple myeloma

AU - Lakshman, A.

AU - Alhaj Moustafa, M.

AU - Rajkumar, S Vincent

AU - Dispenzieri, Angela

AU - Gertz, Morie

AU - Buadi, F. K.

AU - Lacy, Martha

AU - Dingli, David M

AU - Fonder, A. L.

AU - Hayman, S. R.

AU - Hobbs, M. A.

AU - Gonsalves, Wilson

AU - Hwa, Y. L.

AU - Kapoor, Prashant

AU - Leung, N.

AU - Go, R. S.

AU - Lin, Yi

AU - Kourelis, Taxiarchis

AU - Lust, J. A.

AU - Russell, Stephen J

AU - Zeldenrust, S. R.

AU - Kyle, R. A.

AU - Kumar, Shaji K

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 patients with no chromosomal translocation. The median progression-free survival for the three groups were 23.0 (95% confidence interval (CI), 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months, respectively (P<0.01). The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months, respectively (P<0.01). Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months, respectively (P<0.01). The above relationship held true in patients with age <65 years, international staging system (ISS) I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio (HR): 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM are inferior to other standard risk patients.

AB - Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 patients with no chromosomal translocation. The median progression-free survival for the three groups were 23.0 (95% confidence interval (CI), 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months, respectively (P<0.01). The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months, respectively (P<0.01). Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months, respectively (P<0.01). The above relationship held true in patients with age <65 years, international staging system (ISS) I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio (HR): 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM are inferior to other standard risk patients.

UR - http://www.scopus.com/inward/record.url?scp=85045980418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045980418&partnerID=8YFLogxK

U2 - 10.1038/leu.2017.204

DO - 10.1038/leu.2017.204

M3 - Article

VL - 32

SP - 131

EP - 138

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -